<SEC-DOCUMENT>0001193125-24-129562.txt : 20240503
<SEC-HEADER>0001193125-24-129562.hdr.sgml : 20240503
<ACCEPTANCE-DATETIME>20240502181657
ACCESSION NUMBER:		0001193125-24-129562
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240502
FILED AS OF DATE:		20240503
DATE AS OF CHANGE:		20240502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		24910163

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d711543d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as May 02, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d711543dex991.htm">Positive Initial Clinical Data Reported from Immutep&#146;s Efti Combined with Radiotherapy and Checkpoint Inhibitor
 from Phase II Trial in Soft Tissue&nbsp;Sarcoma. </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May 02, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d711543dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g711543dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX/Media Release </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Positive Initial Clinical Data Reported from Immutep&#146;s Efti </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Combined with Radiotherapy and Checkpoint Inhibitor from </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Phase II Trial in Soft Tissue&nbsp;Sarcoma </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Novel triple combination of efti with radiotherapy and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy is well tolerated and has led to encouraging initial efficacy data in <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> Phase II trial </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Four of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that
are rarely observed with standard therapies </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Soft tissue sarcoma is a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">hard-to-treat</FONT></FONT> orphan disease with poor prognosis&nbsp;&amp; high unmet medical need </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Additional data from <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> planned for a medical conference in H2
CY2024 </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 2</B><B></B><B>&nbsp;May </B><B>2024 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP)
(&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces initial encouraging data from <FONT
STYLE="white-space:nowrap">EFTISARC-NEO,</FONT> a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT>
treatment, plus KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) for patients with&nbsp;soft tissue&nbsp;sarcoma (STS). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> study is the first to evaluate efti in a neoadjuvant setting, which takes place before intended
surgery, and the first to combine efti with radiotherapy. Importantly, the neoadjuvant setting allows for the impact of this novel combination to be assessed in the tumour microenvironment (TME). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The triple combination has revealed no new safety findings and has been well tolerated in the first six patients who have completed the 10 weeks of treatment
followed by surgery <FONT STYLE="white-space:nowrap">2-3</FONT> weeks later. Initial efficacy data is very encouraging with 4 of 6 patients (67%) having near-complete responses according to EORTC-STBSDG, which measures responses via tissue pathology
after surgery. These deep responses are rarely seen in STS patients with standard therapeutic approaches including radiotherapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Katarzyna Kozak, M.D.,
Ph.D., and Pawe&#322; Sobczuk, M.D., Ph.D., medical oncologists at the Department of Soft Tissue/Bone Sarcoma and Melanoma at MSCNRIO (Warsaw), and the trial&#146;s principal investigators stated: &#147;The initial pathologic responses from this
novel combination are very encouraging and supportive of the potential synergistic effects of this new therapeutic approach. Indeed we have seen a high degree of hyalinization/fibrosis in the surgical samples which we rarely see with standard
treatments. We look forward to continuing this study.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g711543dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fr&eacute;d&eacute;ric Triebel, M.D., Ph.D, Immutep&#146;s Chief Scientific Officer, added: &#147;We are
pleased to see these early results from <FONT STYLE="white-space:nowrap">EFTISARC-NEO,</FONT> which has allowed efti for the first time to be clinically evaluated in a <FONT STYLE="white-space:nowrap">non-metastatic</FONT> cancer setting. The
ability to evaluate tumour specimens is helping elucidate the significant anti-cancer immune response efti drives through its direct maturation and activation of antigen-presenting cells as an MHC Class&nbsp;II agonist. If the positive trend of
strong pathological responses continues in this rare orphan disease, we will pursue all available avenues to bring this innovative therapy to soft tissue sarcoma patients in need of new, effective therapies in an expeditious manner.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti&#146;s targeting and unique activation of dendritic cells, the most potent professional antigen-presenting cells, as a MHC Class&nbsp;II agonist leads to
broad adaptive and innate immunity to fight cancer, including proliferation of CD8+ cytotoxic T cells that can be armed with radiotherapy-induced tumour antigens. The combination of efti with radiotherapy and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy has the potential to generate a robust anti-tumour immune response in the immunosuppressed tumour microenvironment of soft tissue sarcoma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The open-label <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> Phase II study will treat up to 40 patients and is being conducted by the Maria
Sk&#322;odowska-Curie National Research Institute of Oncology (MSCNRIO) in Warsaw. The trial is primarily funded with an approved grant from the Polish government awarded by the Polish Medical Research Agency program. The study&#146;s primary
endpoint is the pathologic response rate (defined as percentage of tumor hyalinization/fibrosis) to the treatment assessed at the time of surgical resection. The lower the number of viable tumor cells and the higher the extent of
hyalinization/fibrosis observed in patients&#146; tumor specimens will determine the therapy&#146;s effectiveness. For more information, visit clinicaltrials.gov (NCT06128863). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trial is ongoing with 14 patients now enrolled and additional clinical data is planned to be presented at a medical conference in H2 CY2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Soft Tissue Sarcoma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Soft tissue&nbsp;sarcoma
(STS), an orphan disease, represents a high unmet medical need with a poor prognosis. The incidence of STS varies in different regions, with approximately 23,400 cases annually and a crude incidence of 4.7 per 100,000 in Europe, according to the
RARECARE project. In the United States, the number of new cases is estimated to be 13,400 annually with 5,140 deaths, according to the American Cancer Society. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About The Maria&nbsp;Sk&#322;odowska-Curie National Research Institute of Oncology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Maria Sk&#322;odowska Curie National Research Institute of Oncology is the leading Polish comprehensive cancer centre, as well as the primary government
research institution devoted solely to oncology. Founded in 1932 by Maria Sklodowska-Curie, it is currently divided into 28 specialised clinical departments responsible for the diagnostics and therapy of different tumour types such as: Breast Cancer
Clinic, Head and Neck Cancer Clinic, General and Visceral Surgery, Thoracic Surgery, Urology, Gynaecology, Haematology, Soft Tissue/Bone Sarcoma and Melanoma Clinic, Radiation Oncology, Brachytherapy and Diagnostic Radiology, Pathology and Molecular
Medicine and Cell Research, Oncology, Gastroenterology, Cancer Epidemiology and Prevention Division and others. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g711543dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune
disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio
harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information,
please visit <U>www.immutep.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Morrow Sodali </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>c.strong@morrowsodali.com</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the CEO of Immutep Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George
Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g711543dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g711543dsp4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@!"0OMVHV#;TB12W$%O&\LTT<,42EWDE81QHBC)9G; 50!DDG@4I-07O/
ME2[D2G"G!5)R48=&W9'!2?%?X<17'V5O&GASS%;8=NIV[1*0<'=.K&)<>[]J
MYUC,+?E5:-UTN>?+.<KA+DEC:49+I=_Y'>6]U;7<,4]K/#<031K+#-!(LL4L
M; %)(Y$)5T(((8$@@C%=$91DKQ::Z69Z$)PG",Z<E*$E>,HNZMY-$X/^?I3V
M\K%KRV"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MT_C7+\*7XZ$E PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?0?H!7UB^ST21^PQT\MA]44% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !T_#^E&WR#;Y'AGQ8\-?!'Q%>Z0/BDFE?VA9P.^E
MO=ZGJ6E7/V4S?O(_,TV[@>>V\]/N2%@K9*X+'.-6O1H.,:L^5RV5F_R3.3$8
M["8-QCB*RI.2NDU)_P#I*9ZAI%QX9TKPWITFDSZ=8>%K#2K3^SITE6#3+;28
M8$6U=)I6"QVRP*N'=N@R3G-6JD.3VB?N=]3:-:E*DJT9KV3CS*6RY4KMZVM9
M=SDK[XS_  PT]RDWC'2I"O7[&+O45&,@X;3[:92!CJ#6$L;A:=E*JE?;23_)
M,\ZKGN4T'RU,;"+711G+_P!)BT:'A_XI_#_Q-<K9:-XHTZZO7.(K.07-C<S$
M#.V&#4(('F; )PBL< ^E.EB\/6ER4JJE)=+27YI&F&S?+<8^7#8N$WM;WH>2
M^-1&:[\5OA[X;N&M-6\4Z9!=1';+;PFXOYX6!P5EATZ"=HF&1D, 1D'I1/&8
M:DW&=51<=U:3V]$PKYOEN%DX5L7"$H[I<TK6_P "D:7AOQ_X.\6,\?A[Q!I^
MHSQ+O>UB>2*[2/@>8UG<QQS! 2 6\O R,GFKHXBC7_@U%*WDU^:1KA<QP.-7
M^RXF%3LM8O[I*+_ ZBZO+2R@ENKRYAM+:WC::>XN)%@@@B3[TDTLA"Q(HZLQ
M %:RDH)W?*HZOT1USE&G%RFU&,4VV]DEJ_N/-[_XT?##3G,<WC+2I&7@_8OM
M>I $9&-VG6TX[>M<TL;A8-*55*^VDG^29Y=7/<IH2Y*F-A%KHHSE^,8M&MX>
M^)O@/Q1.+70_$NGWEV02EFWGVEW(%&6,-K?0PRS;1RWEHVT$9Q54\7AZK:IU
M5+EZ6:_-(VPV:Y=BY<N'Q4)RZ+WH_P#I:B4]9^+?PYT"X>TU+Q9I<=Q&VR2"
MV^T:A)"XZI*FG03F)AW#[2.]3/&X6FU&551?:TG^29-?.,MPS<:N+A%QW24I
M;?X(R-OPWXZ\)>+!)_PCNO:?JDD*AY;>"1DNHD; 5Y+2=$F12>,F,#/'6M:5
M:E6_A34K?+\'8UPF88+&K_9:\:BCY2B_NFHLU=;U[1O#6EW6M:[J%MI6DV*Q
MO=W]VQBMK=99H[>)I),?*&FEC0>[CUK6UOD=O5QZQ5VO(Q_"WC[P9XV^V_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MAI]W$TNE7ERS?,]WM@NH)';+.;02.2\C4?H'Z'U'0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M:  J#VZ?IB@ "A>@QC^G% "T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!#Y\/\
MST48]P,8J>>"=N9772YE[>C_ ,_H*W]Y!Y\/_/1?S%/FC_,OO0>WH?\ /Z'_
M ($@\^'_ )Z+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\ ,OO0>WH?\_H?
M^!(//A_YZ+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>A_P _H?\
M@2#SX?\ GHOYBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_P R^]![>A_S^A_X
M$@\^'_GHOYBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_S+[T'MZ'_ #^A_P"!
M(//A_P">B_F*.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_ #+[T'MZ'_/Z'_@2
M#SX?^>B_F*.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_,OO0>WH?\ /Z'_ ($@
M\^'_ )Z+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\ ,OO0>WH?\_H?^!(/
M/A_YZ+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>A_P _H?\ @2#S
MX?\ GHOYBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_P R^]![>A_S^A_X$@\^
M'_GHOYBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_S+[T'MZ'_ #^A_P"!(//A
M_P">B_F*.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_ #+[T'MZ'_/Z'_@2#SX?
M^>B_F*.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_,OO0>WH?\ /Z'_ ($@\^'_
M )Z+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\ ,OO0>WH?\_H?^!(//A_Y
MZ+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>A_P _H?\ @2#SX?\
MGHOYBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_P R^]![>A_S^A_X$@\^'_GH
MOYBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_S+[T'MZ'_ #^A_P"!(//A_P">
MB_F*.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_ #+[T'MZ'_/Z'_@2#SX?^>B_
MF*.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_,OO0>WH?\ /Z'_ ($@\^'_ )Z+
M^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\ ,OO0>WH?\_H?^!(//A_YZ+^8
MHYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>A_P _H?\ @2#SX?\ GHOY
MBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_P R^]![>A_S^A_X$@\^'_GHOYBC
MFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_S+[T'MZ'_ #^A_P"!(//A_P">B_F*
M.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_ #+[T'MZ'_/Z'_@2#SX?^>B_F*.:
M/\R^]![>A_S^A_X$@\^'_GHOYBCFC_,OO0>WH?\ /Z'_ ($@\^'_ )Z+^8HY
MH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\ ,OO0>WH?\_H?^!(//A_YZ+^8HYH_
MS+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>A_P _H?\ @2#SX?\ GHOYBCFC
M_,OO0>WH?\_H?^!(//A_YZ+^8HYH_P R^]![>A_S^A_X$@\^'_GHOYBCFC_,
MOO0>WH?\_H?^!(//A_YZ+^8HYH_S+[T'MZ'_ #^A_P"!(//A_P">B_F*.:/\
MR^]![>A_S^A_X$@\^'_GHOYBCFC_ #+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^
M]![>A_S^A_X$@\^'_GHOYBCFC_,OO0>WH?\ /Z'_ ($@\^'_ )Z+^8HYH_S+
M[T'MZ'_/Z'_@2#SX?^>B_F*.:/\ ,OO0>WH?\_H?^!(//A_YZ+^8HYH_S+[T
M'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>A_P _H?\ @2#SX?\ GHOYBCFC_,OO
M0>WH?\_H?^!(//A_YZ+^8HYH_P R^]![>A_S^A_X$@\^'_GHOYBCFC_,OO0>
MWH?\_H?^!(//A_YZ+^8HYH_S+[T'MZ'_ #^A_P"!(//A_P">B_F*.:/\R^]!
M[>A_S^A_X$@\^'_GHOYBCFC_ #+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>
MA_S^A_X$@\^'_GHOYBCFC_,OO0>WH?\ /Z'_ ($@\^'_ )Z+^8HYH_S+[T'M
MZ'_/Z'_@2#SX?^>B_F*.:/\ ,OO0>WH?\_H?^!(//A_YZ+^8HYH_S+[T'MZ'
M_/Z'_@2#SX?^>B_F*.:/\R^]![>A_P _H?\ @2#SX?\ GHOYBCFC_,OO0>WH
M?\_H?^!(//A_YZ+^8HYH_P R^]![>A_S^A_X$@\^'_GHOYBCFC_,OO0>WH?\
M_H?^!(//A_YZ+^8HYH_S+[T'MZ'_ #^A_P"!(//A_P">B_F*.:/\R^]![>A_
MS^A_X$@\^'_GHOYBCFC_ #+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>A_S^
MA_X$@\^'_GHOYBCFC_,OO0>WH?\ /Z'_ ($@\^'_ )Z+^8HYH_S+[T'MZ'_/
MZ'_@2#SX?^>B_F*.:/\ ,OO0>WH?\_H?^!(//A_YZ+^8HYH_S+[T'MZ'_/Z'
M_@2#SX?^>B_F*.:/\R^]![>A_P _H?\ @2#SX?\ GHOYBCFC_,OO0>WH?\_H
M?^!(//A_YZ+^8HYH_P R^]![>A_S^A_X$@\^'_GHOYBCFC_,OO0>WH?\_H?^
M!(//A_YZ+^8HYH_S+[T'MZ'_ #^A_P"!(//A_P">B_F*.:/\R^]![>A_S^A_
MX$@\^'_GHOYBCFC_ #+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>A_S^A_X$
M@\^'_GHOYBCFC_,OO0>WH?\ /Z'_ ($@\^'_ )Z+^8HYH_S+[T'MZ'_/Z'_@
M2#SX?^>B_F*.:/\ ,OO0>WH?\_H?^!(//A_YZ+^8HYH_S+[T'MZ'_/Z'_@2#
MSX?^>B_F*.:/\R^]![>A_P _H?\ @2#SX?\ GHOYBCFC_,OO0>WH?\_H?^!(
M//A_YZ+^8HYH_P R^]![>A_S^A_X$@-Q"/\ EHOY@T<T?YE]XGB*"_Y>Q_\
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M^2K]S#^R<_\ ^@?$_<_\P_X5A\3O^A1\2_\ @'/_ (T?5L=_)5^YA_9.?_\
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MOW,/[)S_ /Z!\3]S_P P_P"%8?$[_H4?$O\ X!S_ .-'U;'?R5?N8?V3G_\
MT#XG[G_F'_"L/B=_T*/B7_P#G_QH^K8[^2K]S#^R<_\ ^@?$_<_\P_X5A\3O
M^A1\2_\ @'/_ (T?5L=_)5^YA_9.?_\ 0/B?N?\ F'_"L/B=_P!"CXE_\ Y_
M\:/JV._DJ_<P_LG/_P#H'Q/W/_,/^%8?$[_H4?$O_@'/_C1]6QW\E7[F']DY
M_P#] ^)^Y_YA_P *P^)W_0H^)?\ P#G_ ,:/JV._DJ_<P_LG/_\ H'Q/W/\
MS#_A6'Q._P"A1\2_^ <_^-'U;'?R5?N8?V3G_P#T#XG[G_F'_"L/B=_T*/B7
M_P  Y_\ &CZMCOY*OW,/[)S_ /Z!\3]S_P P_P"%8?$[_H4?$O\ X!S_ .-'
MU;'?R5?N8?V3G_\ T#XG[G_F'_"L/B=_T*/B7_P#G_QH^K8[^2K]S#^R<_\
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M^%8?$[_H4?$O_@'/_C1]6QW\E7[F']DY_P#] ^)^Y_YA_P *P^)W_0H^)?\
MP#G_ ,:/JV._DJ_<P_LG/_\ H'Q/W/\ S#_A6'Q._P"A1\2_^ <_^-'U;'?R
M5?N8?V3G_P#T#XG[G_F'_"L/B=_T*/B7_P  Y_\ &CZMCOY*OW,/[)S_ /Z!
M\3]S_P P_P"%8?$[_H4?$O\ X!S_ .-'U;'?R5?N8?V3G_\ T#XG[G_F'_"L
M/B=_T*/B7_P#G_QH^K8[^2K]S#^R<_\ ^@?$_<_\P_X5A\3O^A1\2_\ @'/_
M (T?5L=_)5^YA_9.?_\ 0/B?N?\ F'_"L/B=_P!"CXE_\ Y_\:/JV._DJ_<P
M_LG/_P#H'Q/W/_,/^%8?$[_H4?$O_@'/_C1]6QW\E7[F']DY_P#] ^)^Y_YA
M_P *P^)W_0H^)?\ P#G_ ,:/JV._DJ_<P_LG/_\ H'Q/W/\ S#_A6'Q._P"A
M1\2_^ <_^-'U;'?R5?N8?V3G_P#T#XG[G_F'_"L/B=_T*/B7_P  Y_\ &CZM
MCOY*OW,/[)S_ /Z!\3]S_P P_P"%8?$[_H4?$O\ X!S_ .-'U;'?R5?N8?V3
MG_\ T#XG[G_F'_"L/B=_T*/B7_P#G_QH^K8[^2K]S#^R<_\ ^@?$_<_\P_X5
MA\3O^A1\2_\ @'/_ (T?5L=_)5^YA_9.?_\ 0/B?N?\ F'_"L/B=_P!"CXE_
M\ Y_\:/JV._DJ_<P_LG/_P#H'Q/W/_,/^%8?$[_H4?$O_@'/_C1]6QW\E7[F
M']DY_P#] ^)^Y_YA_P *P^)W_0H^)?\ P#G_ ,:/JV._DJ_<P_LG/_\ H'Q/
MW/\ S#_A6'Q._P"A1\2_^ <_^-'U;'?R5?N8?V3G_P#T#XG[G_F'_"L/B=_T
M*/B7_P  Y_\ &CZMCOY*OW,/[)S_ /Z!\3]S_P P_P"%8?$[_H4?$O\ X!S_
M .-'U;'?R5?N8?V3G_\ T#XG[G_F'_"L/B=_T*/B7_P#G_QH^K8[^2K]S#^R
M<_\ ^@?$_<_\P_X5A\3O^A1\2_\ @'/_ (T?5L=_)5^YA_9.?_\ 0/B?N?\
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M'_"L/B=_T*/B7_P#G_QH^K8[^2K]S#^R<_\ ^@?$_<_\P_X5A\3O^A1\2_\
M@'/_ (T?5L=_)5^YA_9.?_\ 0/B?N?\ F'_"L/B=_P!"CXE_\ Y_\:/JV._D
MJ_<P_LG/_P#H'Q/W/_,/^%8?$[_H4?$O_@'/_C1]6QW\E7[F']DY_P#] ^)^
MY_YA_P *P^)W_0H^)?\ P#G_ ,:/JV._DJ_<P_LG/_\ H'Q/W/\ S#_A6'Q.
M_P"A1\2_^ <_^-'U;'?R5?N8?V3G_P#T#XG[G_F'_"L/B=_T*/B7_P  Y_\
M&CZMCOY*OW,/[)S_ /Z!\3]S_P P_P"%8?$[_H4?$O\ X!S_ .-'U;'?R5?N
M8?V3G_\ T#XG[G_F'_"L/B=_T*/B7_P#G_QH^K8[^2K]S#^R<_\ ^@?$_<_\
MP_X5A\3O^A1\2_\ @'/_ (T?5L=_)5^YA_9.?_\ 0/B?N?\ F'_"L/B=_P!"
MCXE_\ Y_\:/JV._DJ_<P_LG/_P#H'Q/W/_,/^%8?$[_H4?$O_@'/_C1]6QW\
ME7[F']DY_P#] ^)^Y_YA_P *P^)W_0H^)?\ P#G_ ,:/JV._DJ_<P_LG/_\
MH'Q/W/\ S#_A6'Q._P"A1\2_^ <_^-'U;'?R5?N8?V3G_P#T#XG[G_F'_"L/
MB=_T*/B7_P  Y_\ &CZMCOY*OW,/[)S_ /Z!\3]S_P P_P"%8?$[_H4?$O\
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CX8'H* YGW?WA@>@H#F?=_>&!Z#CVZ8J9;>A4-79ZI=&?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
